[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628677":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-1701, apatinib, and SOX","EXPERIMENTAL",null,[13,14,15],"Drug: SHR-1701","Drug: apatinib","Drug: S-1 & Oxaliplatin",{"label":17,"type":10,"description":11,"interventionNames":18},"SHR-1701 and SOX",[13,15],[20,25,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","SHR-1701","SHR-1701, 1800mg, Q3w",[17,9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"apatinib","apatinib 250mg，Q3W",[9],{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"S-1 & Oxaliplatin","S-1, Oxaliplatin, Q3w",[17,9],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Xiaofeng Chen, MD","CONTACT","0086-13585172066","chenxiaofengnimu@163.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"The First Affiliated Hospital of Nanjing Medical University","RECRUITING","Nanjing","Jiangsu","China","CN",{"type":48,"coordinates":49},"Point",[50,51],118.77778,32.06167,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":11,"phoneExt":11,"email":11},"Xiaofeng Chen",{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628677","phase-2-shr-1701-with-or-without-apatinib-in-combination-with-chemotherapy-as-neoadjuvant-therapy-for-gastric-cancer-100628677",false,"NCT07464756","SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer","A Prospective Exploratory Study of SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Patients voluntarily participate in this study and provide signed informed consent;\n2. Age ≥18 years old;\n3. Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (Siewert Type II and Type III adenocarcinoma are permitted);\n4. Clinically staged as T3-4aN+M0 by CT or MRI (per AJCC 8th edition), deemed resectable\n5. No prior antitumor therapy (e.g., surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.);\n6. Plan to proceed to surgery after completion of neoadjuvant therapy;\n7. Able to swallow tablets normally;\n8. Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n9. Estimated life expectancy ≥12 months;\n10. Has adequate organ function.\n11. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose and must agree to use a highly effective method of contraception during the study and for 3 months after the last dose of SHR-1701, or 8 weeks after apatinib, or 6 months after chemotherapy (whichever is longer). Male subjects with partners of childbearing potential must be surgically sterile or agree to use a highly effective method of contraception during the study and for 3 months after the last dose of SHR-1701, or 8 weeks after apatinib, or 3 months after chemotherapy (whichever is longer), and must not donate sperm during the study.\n\nExclusion Criteria:\n\n1. Known HER2 positive\n2. Need transthoracic surgical approach Based on the investigator's judgment\n3. Known peritoneal metastasis or positive peritoneal cytology (CY1P0) or T4b (according to AJCC 8th edition); 4 Presence of unresectable factors, including unresectability due to tumor-related reasons, contraindications to surgery, or refusal of surgery;\n\n5\\. Previous or concurrent malignancies, except for cured basal cell carcinoma of skin, carcinoma in situ of cervix, and carcinoma in situ of breast; 6. Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy)； 7. Known hypersensitivity to any of the study drugs or excipients; 8. Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.); 9. Congenital or acquired immune deficiency (e.g. HIV infected)","ALL","18 Years",{"count":68,"type":69},80,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","This study is a multicenter, randomized, two-cohort clinical trial to evaluate the efficacy and safety of SHR-1701 with or without apatinib in combined with chemotherapy of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.",[75],"Gastric Adenocarcinoma","2026-07-14",{"date":78,"type":79},"2026-07-16","ACTUAL",{"date":81,"type":79},"2026-04-03",{"date":83,"type":69},"2030-07-31",{"name":5,"class":6},1]